• About
  • Privacy Policy
  • Terms Of Use
  • Contact
Saturday, January 28, 2023
Pharma Info Nepal
  • Home
  • Loksewa
  • License
  • Questions
  • Vacancy
  • Downloads
  • Notice
No Result
View All Result
  • Home
  • Loksewa
  • License
  • Questions
  • Vacancy
  • Downloads
  • Notice
No Result
View All Result
Pharma Info Nepal
No Result
View All Result
Home Updates

FDA Statement on Johnson & Johnson COVID-19 Vaccine

FDA Statement on Johnson & Johnson COVID-19 Vaccine

Nabin Bista by Nabin Bista
April 13, 2021
in Updates
0
FDA Statement on Johnson & Johnson COVID-19 Vaccine
191
VIEWS
Share on FacebookShare on Twitter

FDA Statement on Johnson & Johnson COVID-19 Vaccine

Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine, severe type of blood clot in individuals after receiving the J&J vaccine

As of April 12, more than 6.8 million doses of the Johnson & Johnson (Janssen) vaccine have been administered in the U.S. CDC and FDA are reviewing data involving six reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the J&J vaccine. In these cases, a type of blood clot called cerebral venous sinus thrombosis (CVST) was seen in combination with low levels of blood platelets (thrombocytopenia). All six cases occurred among women between the ages of 18 and 48, and symptoms occurred 6 to 13 days after vaccination. Treatment of this specific type of blood clot is different from the treatment that might typically be administered. Usually, an anticoagulant drug called heparin is used to treat blood clots. In this setting, administration of heparin may be dangerous, and alternative treatments need to be given.

CDC will convene a meeting of the Advisory Committee on Immunization Practices (ACIP) on Wednesday to further review these cases and assess their potential significance. FDA will review that analysis as it also investigates these cases. Until that process is complete, we are recommending a pause in the use of this vaccine out of an abundance of caution. This is important, in part, to ensure that the health care provider community is aware of the potential for these adverse events and can plan for proper recognition and management due to the unique treatment required with this type of blood clot.

Right now, these adverse events appear to be extremely rare. COVID-19 vaccine safety is a top priority for the federal government, and we take all reports of health problems following COVID-19 vaccination very seriously. People who have received the J&J vaccine who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider. Health care providers are asked to report adverse events to the Vaccine Adverse Event Reporting System at https://vaers.hhs.gov/reportevent.html.

On February 27, 2021, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the third vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The EUA allows the Janssen COVID-19 Vaccine to be distributed in the U.S. for use in individuals 18 years of age and older.

Common Side Effects

The most commonly reported side effects were pain at the injection site, headache, fatigue, muscle aches and nausea. Most of these side effects occurred within 1-2 days following vaccination and were mild to moderate in severity and lasted 1-2 days.


  • FDA Approved Drugs in 2020
  • Why You Should Not Use Ivermectin to Treat or Prevent COVID-19

 

 

Tags: Medicine InformationPharmacy Updates
Previous Post

“Pharmacy: Always trusted for your health” is the theme of this year’s World Pharmacists Day

Next Post

Adverse Drug Reaction (ADR)

Nabin Bista

Nabin Bista

Hello, Thank You for visiting my blog I am Nabin Bista, Dedicated and self motivated young Pharmacist from Nepal. Blogging is my passion. I am studying B Pharmacy at Institute of Medicine - IOM. If you want me to write about any posts that you found confusing/difficult, please mention in the comments below.

Related Posts

FDA-Approved HIV Medicines

FDA Approved HIV Medicines

January 26, 2023
Combined Oral Contraceptives (COC)

Combined Oral Contraceptives (COC)

January 17, 2023
Novel Drug Approvals for 2022

Novel Drug Approvals for 2022

January 3, 2023
B Pharmacy Entrance Exam Notice 2079

B Pharmacy Entrance Exam Notice 2079

January 2, 2023
Load More
Next Post
Adverse Drug Reaction (ADR)

Adverse Drug Reaction (ADR)

Discussion about this post

Recommended

Vacancy Announcement Pharmacist Maruti Pharmaceuticals

Vacancy Announcement Pharmacist Maruti Pharmaceuticals

2 years ago
Vacancy Announcement Long Term Technical Assistance Consultant

Vacancy Announcement Long Term Technical Assistance Consultant

5 months ago

Don't Miss

FDA-Approved HIV Medicines

FDA Approved HIV Medicines

January 26, 2023
Combined Oral Contraceptives (COC)

Combined Oral Contraceptives (COC)

January 17, 2023
Nepal Pharmacy Council 21st Name Registration Exam Application Form Notice

Nepal Pharmacy Council 21st Name Registration Exam Application Form Notice

January 9, 2023
Nepal Pharmacy Counci Notice

Nepal Pharmacy Council Notice

January 5, 2023

About Pharma Info Nepal

Pharma Info Nepal (Nabin’s Blog) was initiated in 2019 with the aim of providing relevant and accurate information for pharmacy, nursing and other health professionals. Since then it is conveying health related educational and informational updates of Nepal. It serves as a source for learning materials on diverse topics relating to medicine intended basically for pharmacy and nursing students. It covers job opportunities, question collections for pharmacy license, nursing license as well as various competitive exams.

Our readers rely on us for the well referenced and latest updates collected from the reliable sites.

Follow us

  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Instagram

Information Reader

Contents (text, image, graphics, documents and other materials) published on this portal are collected from other relevant sources with the sole purpose of sharing information. Contents and features are subject to change and all rights reserved to Pharma info Nepal. The information presented on this web portal and its official social media handles have no affiliation to any organization that author is involved with either professionally or personally.

If you have found anything displayed incorrectly or have further suggestions on improving our effort, please do not hesitate to reach out at pharmainfonepal1@gmail.com !
We hope you find Pharma info Nepal a helpful site. Thanks !!!

Categories

  • B Pharmacy
  • Colleges
  • D Pharmacy
  • Downloads
  • License
  • Loksewa
  • M Pharmacy
  • Medicinal Chemistry
  • Notice
  • Nursing
  • Pharmacognosy
  • Pharmacology
  • Questions
  • Scholarship
  • Study Materials
  • Syllabus
  • Updates
  • Vacancy

DOWNLOADS

Pharmacy Book 

Pharmacy Act and Guidelines

About Pharma Info Nepal

About Admin

  • About
  • Privacy Policy
  • Terms Of Use
  • Contact

© 2021 Nabin's Blog

No Result
View All Result
  • Home
  • Loksewa
  • License
  • Questions
  • Vacancy
  • Downloads
  • Notice

© 2021 Nabin's Blog

error: